iiinova — where your digital self keeps evolving

Reposted by Alex Schurer

David Shechter @dshechter.bsky.social · 10/04/2025

Many years of effort by @alexkschurer.bsky.social and @humaira2204.bsky.social , following initial work by Maxim Maron, lead us to this discovery. /2

111

Reposted by Alex Schurer

David Shechter @dshechter.bsky.social · 10/04/2025

We discovered a new AML vulnerability: TTLL4 glutamylates NPM1c and helps leukemia cells thrive. Knock it down and cells differentiate and survival improves. Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1

bit.ly

TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia

NPM1-mutated acute myeloid leukemia (AML) is defined by aberrant cytoplasmic localization of the mutant NPM1c protein, and therapeutic strategies targeting this specific disease remain limited. Here, ...

132

Reposted by Alex Schurer

Shira G-S, PhD @thehematopoet.bsky.social · 04/12/2024

Overwhelmed by all of the exciting new research on chromatin modifiers in AML? Find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in SCTM! @alexkschurer.bsky.social @gritsmanlab.bsky.social academic.oup.com/stcltm/advan...

academic.oup.com

Targeting chromatin modifying complexes in acute myeloid leukemia

Abstract. Acute myeloid leukemia (AML) is a devastating hematologic malignancy with high rates of relapse, which can, in part, be attributed to the dysregu

1269